Citadel Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-6,600
| Closed | -$14.6K | – | 15477 |
|
|
2023
Q2 | $14.6K | Sell |
6,600
-2,800
| -30% | -$5.81K | ﹤0.01% | 12995 |
|
|
2023
Q1 | $23.9K | Buy |
9,400
+1,700
| +22% | +$3.36K | ﹤0.01% | 12924 |
|
|
2022
Q4 | $14.4K | Buy |
+7,700
| New | +$19.2K | ﹤0.01% | 13394 |
|
|
2021
Q4 | – | Sell |
-20,000
| Closed | -$97K | – | 15120 |
|
|
2021
Q3 | $97K | Buy |
20,000
+1,100
| +6% | +$6.06K | ﹤0.01% | 12918 |
|
|
2021
Q2 | $129K | Sell |
18,900
-5,000
| -21% | -$40.4K | ﹤0.01% | 12672 |
|
|
2021
Q1 | $169K | Buy |
23,900
+6,600
| +38% | +$47.5K | ﹤0.01% | 11920 |
|
|
2020
Q4 | $108K | Buy |
+17,300
| New | +$102K | ﹤0.01% | 10177 |
|
|
2019
Q1 | – | Sell |
-13,500
| Closed | -$69K | – | 10059 |
|
|
2018
Q4 | $69K | Sell |
13,500
-9,000
| -40% | -$68.3K | ﹤0.01% | 8399 |
|
|
2018
Q3 | $218K | Sell |
22,500
-10,500
| -32% | -$106K | ﹤0.01% | 8085 |
|
|
2018
Q2 | $337K | Buy |
33,000
+6,700
| +25% | +$75.8K | ﹤0.01% | 7015 |
|
|
2018
Q1 | $342K | Buy |
26,300
+9,900
| +60% | +$147K | ﹤0.01% | 6526 |
|
|
2017
Q4 | $294K | Buy |
16,400
+6,800
| +71% | +$142K | ﹤0.01% | 6500 |
|
|
2017
Q3 | $241K | Buy |
9,600
+100
| +1% | +$2.33K | ﹤0.01% | 6402 |
|
|
2017
Q2 | $229K | Sell |
9,500
-24,600
| -72% | -$544K | ﹤0.01% | 6358 |
|
|
2017
Q1 | $656K | Buy |
+34,100
| New | +$537K | ﹤0.01% | 4619 |
|
Citadel Advisors's PRTK Position: Q1 2023 in Review
Citadel Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q1 2023, closing a stake of 203,159 shares — an estimated $401K sold.
Citadel Advisors first reported a position in PRTK in Q2 2015 and held it in 24 quarters. The position peaked at $2.86M in Q2 2018. 63 funds tracked by Wall St. Rank hold PRTK as of Q1 2023.
- Citadel Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- Citadel Advisors sold 203,159 Paratek Pharmaceuticals, Inc. shares in Q1 2023, an estimated $401K.
- Citadel Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2015 and held it in 24 quarters.
- Citadel Advisors's Paratek Pharmaceuticals, Inc. position peaked at $2.86M in Q2 2018.
- 63 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q1 2023.
Based on Citadel Advisors's 13F filing for Q1 2023, filed 15 May 2023.